Clinical Trial Update: Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sorafenib in combination with temsirolimus or tipifarnib in patients with stage IV malignant melanoma that cannot be surgicall…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Sorafenib (Sorafenib)
• Temsirolimus (temsirolimus)
• Tipifarnib (tipifarnib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2012-07-10